These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28813081)

  • 1. Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS.
    Fávero FM; Voos MC; Castro I; Caromano FA; Oliveira ASB
    Arq Neuropsiquiatr; 2017 Aug; 75(8):515-522. PubMed ID: 28813081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy.
    Zoccolella S; Beghi E; Palagano G; Fraddosio A; Guerra V; Samarelli V; Lepore V; Simone IL; Lamberti P; Serlenga L; Logroscino G;
    Eur J Neurol; 2007 Mar; 14(3):262-8. PubMed ID: 17355545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Moore DH
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD001447. PubMed ID: 22419278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riluzole and other prognostic factors in ALS: a population-based registry study in Italy.
    Mandrioli J; Malerba SA; Beghi E; Fini N; Fasano A; Zucchi E; De Pasqua S; Guidi C; Terlizzi E; Sette E; Ravasio A; Casmiro M; Salvi F; Liguori R; Zinno L; Handouk Y; Rizzi R; Borghi A; Rinaldi R; Medici D; Santangelo M; Granieri E; Mussuto V; Aiello M; Ferro S; Vinceti M;
    J Neurol; 2018 Apr; 265(4):817-827. PubMed ID: 29404735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features and prognosis of amyotrophic lateral sclerosis in Africa: the TROPALS study.
    Luna J; Diagana M; Ait Aissa L; Tazir M; Ali Pacha L; Kacem I; Gouider R; Henning F; Basse A; Cisse O; Balogou AAK; Kombate D; Agbetou M; Houinato D; Millogo A; Agba T; Belo M; Penoty M; Raymondeau-Moustafa M; Hamidou B; Couratier P; Preux PM; Marin B;
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):20-29. PubMed ID: 30242088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyotrophic lateral sclerosis progression: Iran-ALS clinical registry, a multicentre study.
    Shamshiri H; Fatehi F; Davoudi F; Mir E; Pourmirza B; Abolfazli R; Etemadifar M; Harirchian MH; Gharagozli K; Ayromlou H; Basiri K; Zamani B; Rohani M; Sedighi B; Roudbari A; Delavar Kasmaei H; Nikkhah K; Ranjbar Naeini A; Nafissi S
    Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(7-8):506-11. PubMed ID: 26437387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying drug therapies.
    Brooks BR; Sanjak M
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():68-75. PubMed ID: 15512878
    [No Abstract]   [Full Text] [Related]  

  • 9. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
    Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
    J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort.
    Talman P; Duong T; Vucic S; Mathers S; Venkatesh S; Henderson R; Rowe D; Schultz D; Edis R; Needham M; Macdonnell R; McCombe P; Birks C; Kiernan M
    BMJ Open; 2016 Sep; 6(9):e012054. PubMed ID: 27694488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riluzole for the treatment of amyotrophic lateral sclerosis.
    Saitoh Y; Takahashi Y
    Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riluzole does not improve lifespan or motor function in three ALS mouse models.
    Hogg MC; Halang L; Woods I; Coughlan KS; Prehn JHM
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 Aug; 19(5-6):438-445. PubMed ID: 29221425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
    Lacomblez L; Bensimon G; Leigh PN; Guillet P; Meininger V
    Lancet; 1996 May; 347(9013):1425-31. PubMed ID: 8676624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2007 Jan; (1):CD001447. PubMed ID: 17253460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: a population based study in Modena, Italy.
    Georgoulopoulou E; Fini N; Vinceti M; Monelli M; Vacondio P; Bianconi G; Sola P; Nichelli P; Mandrioli J
    Amyotroph Lateral Scler Frontotemporal Degener; 2013 Sep; 14(5-6):338-45. PubMed ID: 23373475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates of progression of weight and forced vital capacity as relevant measurement to adapt amyotrophic lateral sclerosis management for patient Result of a French multicentre cohort survey.
    Clavelou P; Blanquet M; Peyrol F; Ouchchane L; Gerbaud L
    J Neurol Sci; 2013 Aug; 331(1-2):126-31. PubMed ID: 23809193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiological and clinical features of amyotrophic lateral sclerosis in a Tunisian cohort.
    Kacem I; Sghaier I; Bougatef S; Nasri A; Gargouri A; Ajroud-Driss S; Gouider R
    Amyotroph Lateral Scler Frontotemporal Degener; 2020 Feb; 21(1-2):131-139. PubMed ID: 31858811
    [No Abstract]   [Full Text] [Related]  

  • 19. An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000.
    Traynor BJ; Alexander M; Corr B; Frost E; Hardiman O
    J Neurol; 2003 Apr; 250(4):473-9. PubMed ID: 12700914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis.
    Andrews JA; Jackson CE; Heiman-Patterson TD; Bettica P; Brooks BR; Pioro EP
    Amyotroph Lateral Scler Frontotemporal Degener; 2020 Nov; 21(7-8):509-518. PubMed ID: 32573277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.